MELBOURNE, Australia--(BUSINESS WIRE)--Melbourne-based biotechnology company Avexa Limited (ASX:AVX) announced today positive 24 week data from the phase 2b clinical trial of apricitabine (ATC). The data demonstrate that, in over 80% of patients treated with ATC, the level of HIV in the blood was reduced to below detectable levels after 24 weeks. This was markedly better than those patients on the 3TC control.
